Related coverage linked through entity extraction aliases.
Aug 23, 2026
Alumis reported that 54% of psoriasis patients achieved complete skin clearance (PASI 100) at 48 weeks in the ONWARD3 study, with 75% achieving PASI 90. The company plans to submit an NDA for envudeucitinib in Q4 2026.
Aug 17, 2026
Real-world and trial data show ixekizumab and deucravacitinib provide durable efficacy in psoriatic arthritis. Ixekizumab achieved high remission rates and drug retention over 24 months, while deucravacitinib improved outcomes across multiple disease domains in the phase III POETYK PsA-2 trial.
Jul 27, 2026
InnoCare's TYK2 inhibitor fadeucravacitinib met primary and secondary endpoints in a Phase 3 psoriasis trial, with a favorable safety profile. InnoCare plans to seek regulatory approval.
Feb 28, 2025
Drug Hunter has opened nominations for the 2025 Molecules of the Year following the announcement of the final Molecules of the Month for 2025. Eligible molecules must have been first disclosed or had a major update in 2025.
Dec 19, 2025
Takeda announced positive Phase 3 results for zasocitinib in adults with moderate-to-severe plaque psoriasis, meeting all 44 endpoints. The company is also conducting a Phase 3 trial in pediatric patients.
Feb 13, 2026
The FDA is set to make approval decisions on five drug applications in March 2026, including treatments for psoriatic arthritis, dry eye disease, hypothalamic obesity, cholestatic pruritus, and a rare genetic disorder.
